Bevacizumab is a humanized monoclonal antibody that targets vascular endothelial growth factor. As a result of concerns for potential infusion-related hypersensitivity reactions (HSRs), initial phase ...

Sintilimab combined with lenvatinib versus hepatic artery infusion chemotherapy (HAIC) for neoadjuvant treatment of resectable primary hepatocellular carcinoma with high risk of recurrence: A ...

BELLA trial evaluates relacorilant, nab-paclitaxel, and Avastin in platinum-resistant ovarian cancer patients across multiple regions. Phase 3 ROSELLA trial showed relacorilant improved ...

Nationally available price reductions for bevacizumab (originator and biosimilars) have been agreed with the Medicines Procurement and Supply Chain. The prices agreed through the framework are ...